A Phase II Trial of Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Trial Profile

A Phase II Trial of Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Cytomegalovirus-specific T-cell therapy Atara/MSKCC (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 27 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
    • 27 Feb 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
    • 05 Apr 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top